Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic–pharmacodynamic relationships

Abstract

Sarizotan 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl) pyridin-3-yl]methyl] methenamine, showed an in vivo pharmaco-EEG profile resembling that of methylphenidate which is used in attention deficit/hyperactivity disorder (ADHD). In turn, we tested sarizotan against impulsivity in juvenile rats measuring the choice for large delayed vs. a… (More)
DOI: 10.1007/s00702-015-1392-6

Topics

8 Figures and Tables

Cite this paper

@article{Danysz2015EffectsOS, title={Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic–pharmacodynamic relationships}, author={Wojciech Danysz and Gunnar Flik and Andrew C McCreary and Carsten Tober and Wilfried Dimpfel and Jean Charles Bizot and Richard M. Kostrzewa and Russell Brown and Claudia C. Jatzke and Sergio Greco and Ann-Kristin Jenssen and Christopher G. Parsons}, journal={Journal of Neural Transmission}, year={2015}, volume={122}, pages={1221-1238} }